Group | Control (N = 21) | COVID-19 (N = 17) | P value |
---|---|---|---|
Protocol | Â | Â | 0.064b |
Antagonist | 16 | 8 | Â |
Long luteal | 5 | 9 | Â |
Total dosage of gonadotropin (IU) | 2700.0 (2400 to 4350) | 2825.0 (2375 to 3900) | 0.705 c |
Duration of COS (d) | 10.5 (10 to 11) | 11.5 (11 to 12) | 0.075c |
T1 | Â | Â | Â |
P | 2.12 (0.75 to 3.07) | 2.08 (1.54 to 3.05) | 0.758c |
E2 | 671.14 (104.35 to 3672.88) | 574.93 (344.17 to 1438.63) | 0.988c |
LH | 4.20 ± 1.80 | 1.78 ± 1.86 | 0.000a |
T2 | Â | Â | Â |
P | 2.52 ± 1.55 | 2.82 ± 1.43 | 0.523a |
E2 | 4928.50 ± 3354.94 | 3567.29 ± 2299.30 | 0.173 a |
LH | 2.17 ± 1.74 | 1.91 ± 1.47 | 0.356a |
T3 | Â | Â | Â |
P | 3.51 ± 2.34 | 3.91 ± 1.04 | 0.489a |
E2 | 8992.32 ± 5869.93 | 10996.26 ± 5687.55 | 0.296a |
LH | 1.75 (1.04 to 2.24) | 1.41 (0.84 to 2.64) | 0.177c |